Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor (TKI), is the new "rst line standard of care in metastatic non‐small cell lung cancer (NSCLC) based on improvements in overall survival (OS), control of central nervous system (CNS) disease, and a superior toxicity pro"le. This commentary highlights interim results from the ADAURA trial, continuing the e!ort to establish a role for EGFR TKIs in the adjuvant setting.…